Novartis

View All

Cluster headache
Lilly overtakes rivals with its Cluster Headache approval

In layman’s language, Cluster headache is a headache disorder that occurs in cyclical patterns. The term cluster headache itself defines the condition that these attacks occur in groups, or “clusters.” During a cluster cycle, brief, excruciatingly severe headache attacks recur between 1-8 times per day. Known as on...

Find More

Pharma news
Notizia

Sanofi’s Isatuximab combo extends lives in multiple myeloma Phase III trials of Sanofi’s investigational anti-CD38 monoclonal antibody, isatuximab combination therapy were successful in lowering down the multiple myeloma tumor rate in 60% of the patients in comparison to 35% reduction in the patients taking the...

Find More

World Pharma News
The Business Cocktail

Iovance infuses USD 75 M to boost Cancer therapy Iovance Biotherapeutics is all set to build a 136,000-square-foot facility in Philadelphia to develop cancer therapies using its tumour-infiltrating lymphocyte (TIL) technology. Building the new facility will cost the Iovance around USD 75 Million. The biotherapeu...

Find More

Meet the World’s most expensive drug: Zolgensma

The U.S. FDA recently approved the much talked about Novartis’s drug Zolgensma for treating a life-threatening condition Spinal Muscular Atrophy (SMA).  SMA is a neuromuscular disorder that worsens the muscles over time. It happens due to a mutation in the SMN1 gene that results in the deficiency of an SMN pro...

Find More

AstraZeneca-Daiichi’s results; Novartis remunerates; Pfizer to acquire Therachon; Gilead & Goldfinch Bio collaboration

AstraZeneca-Daiichi breast cancer treatment scored promising results The breast cancer drug trastuzumab deruxtecan developed by AstraZeneca and Daiichi Sankyo showed positive results in a metastatic breast cancer trial. AstraZeneca remunerated Daiichi Sankyo USD 1.35 billion upfront and guaranteed up to USD 6.9 ...

Find More

Spinal Muscular Atrophy
Spinal Muscular Atrophy Market is expected to augment at a CAGR of 10.42%

Spinal Muscular Atrophy (SMA) is a genetic disorder that affects the part of the nervous system which controls the voluntary movement of limbs and muscles. SMA results in the loss of motor neurons in the Spinal Cord. SMA is one of the most common causes of infant mortality and mobility impairment. Spinal Muscular A...

Find More

MEDICAL MARIJUANA
What can be the scope of Medical Marijuana?

What exactly is Marijuana? In a layman language, Marijuana is the dried buds and leaves of a plant Cannabis sativa favored in warm, wild tropical climates. Earning names like pot, ganja, weed, hemp, hash, etc. it contains around 104 active cannabinoids (CBD). What they do is, they mimic the signal producing che...

Find More

artificial intelligence
The Business Cocktail

Saama Technologies raises USD 40 Million to bolster AI Saama Technologies has got a hefty investment of USD 40million to accelerate its Artificial Intelligence and bolster its use in the branch of Life Sciences. This will help the California based data analytics company to innovate, curate and accelerate the cli...

Find More

The Business Cocktail

Cell Medica receives funds for its cell therapy A USD 8.7 million grant to Cell Medica has been given by Cancer Prevention and Research Institute of Texas (CPRIT) to speed up the clinical development of CMD-502 off-the-shelf chimeric antigen receptor-natural killer T cell (CAR-NKT) cell therapy. The program, su...

Find More

Genentech remunerates Xencor; XPrize upraises fund; GSK gambles

Genentech remunerates Xencor USD 120 Million for global rights Genentech has remunerated USD 120 million upfront to have global rights to IL-15 cytokine therapeutics in preclinical development at Xencor. Xencor is pursuing IL-15, an immune signaling protein, contemplating that it can stimulate natural...

Find More